

**LETTER FOR PCT ARTICLE 34 AMENDMENT OF DESCRIPTION AND CLAIMS**

Date: 2004. 5. 31

**Amendment to the description and the claims under Article 34**

International Application No.: PCT/KR2003/002034

International Filing Date: October 2, 2003

Applicant: B &amp; C BIOPHARM CO., LTD.

633-2, Goan-ri, Baekam-myeon, Yongin-si, Gyeonggi-do 449-863  
Republic of Korea (Tel. 82-31-330-7717)

Agent: LEE, Duck-Rog

YEiLPAT Bldg., 669-17, Yorksam-dong, Kangnam-ku, Seoul 135-915  
Republic of Korea (Tel. 82-2-555-1717)

Applicant's or Agent's File reference: YL03002PCT

Dear Sir(s):

Applicant herewith submits replacement sheets number pages 1 to 11 and 13 to 16 to replace sheets number pages 1 to 11 and 13 to 16, originally filed for this application.

In respect of each claim appearing in the international application based on the replacement sheets submitted herewith, and in accordance with PCT section 205, the claims are as following:

(i) amended: claims 1 to 3

Furthermore, in respect of the description appearing in the international application based on the replacement sheets submitted herewith, in accordance with PCT section 205, the description are as following:

(i) page 1:

1. "More particularly, ~ to" phrase is changed into ", and more particularly novel~" on the 7<sup>th</sup> line.

... Cont'd next page

2. "... (I)" mark is added in the end of formula.
3. "derivatives" is corrected to "derivative" on the 6<sup>th</sup> to the 7<sup>th</sup> lines.
4. "2 hundred" is corrected to "200" on the 21<sup>st</sup> line.

(ii) page 2:

1. "into" is added right after "it is processed" on the 14<sup>th</sup> line.
2. "3,100" to "3,010" on the 8<sup>th</sup> line and "flaviviruses" to "Flaviviruses" on the 27<sup>th</sup> line are corrected respectively.
3. "formation of the virus and RNA replication" to "expression and RNA replication of the virus" on the 12<sup>th</sup> line and "(NS3) of the virus and cofactor(NS2, NS4A, and NS4B)" phrase to "(NS3) and cofactor(NS2, NS4A, and NS4B) of the virus" on the 21<sup>st</sup> to the 22<sup>nd</sup> lines, respectively are changed.
4. "the" on the 9<sup>th</sup> line, "strand" on the 13<sup>th</sup> line and "i.e." on the 16<sup>th</sup> line are deleted respectively.
5. "membrane" to "envelope" on the 6<sup>th</sup> line, "proliferation" to "replication" on the 19<sup>th</sup> line and "part" to "role" on the 24<sup>th</sup> line, respectively are changed.

(iii) page 3:

1. "the" right ahead of "3'-UTR" on the 15<sup>th</sup> line, "it is reported that" right ahead of "-poly(U)-part" on the 21<sup>st</sup> line and "the" right ahead of "most" on the 6<sup>th</sup> line are added respectively.
2. "disclosing translation" on the 8<sup>th</sup> to the 9<sup>th</sup> lines to "initiation of translational" and "has" on the 22<sup>nd</sup> line to "induces" are changed respectively.
3. "when the RNA replication starts" phrase is inserted right ahead of "Reference" on the 26<sup>th</sup> line.

(iv) page 4:

1. "consists of" is corrected to "is an enzyme consisting of" on the 2<sup>nd</sup> line.
2. "According to~." paragraph on the 3<sup>rd</sup> to the 5<sup>th</sup> lines is deleted.
3. "(RBD)" is inserted right ahead of "i.e." on the 6<sup>th</sup> line.
4. "back" is deleted on the 17<sup>th</sup> line.

(v) page 5:

1. "Unfortunately, ~." paragraph on the 10<sup>th</sup> to the 12<sup>th</sup> lines is deleted.
2. "is found because of" is changed to "exist as" on the 14<sup>th</sup> line.
3. "HCV's" on the 23<sup>rd</sup> line and "(replicase" on the 27<sup>th</sup> line are deleted respectively.
4. "motif" is changed to "enzyme" on the 27<sup>th</sup> line.

... Cont'd next page

(vi) page 6:

1. "HCV C relapsed again" phrase is changed to "relapsed into hepatitis C again" on the 17<sup>th</sup> line.
2. "little" to "low", "anti-virus" to "antiviral", "prepare" to "synthesize" and "formula 1" to "formula I" are changed respectively on the 21<sup>st</sup> to the 26<sup>th</sup> lines.
3. "compound" is changed to "small molecule" on the 21<sup>st</sup> line.

(vii) page 7:

1. "these compounds are" phrase is corrected to "this compound is" on the first line.
2. "~derivatives, which are effective for inhibiting hepatitis C virus(HCV), and pharmaceutically acceptable salts and a method for preparing the compounds" is changed to "~ derivative, which is effective for inhibiting the replication of HCV, ~ salts thereof and ~ compound" on the 6<sup>th</sup> to the 8<sup>th</sup> lines.
3. "little" is changed to "low" on the 11<sup>th</sup> line.
4. "there are provided" is changed to "the present invention provides" on the 12<sup>th</sup> line.
5. "... (I)" mark is added in the end of formula.
6. "compounds" on the 16<sup>th</sup> and the 18<sup>th</sup> line to "compound", "formula 1" on the 13<sup>th</sup> and the 19<sup>th</sup> line to "formula I", "derivatives" on the 13<sup>th</sup> line to "derivative" and "salts" on the 14<sup>th</sup> line to "salt" are corrected respectively.
7. "are available" is added right after "free acids" on the 18<sup>th</sup> line.

(viii) page 8:

1. "4-trifluoroacetic acid" on the 3<sup>rd</sup> line to "trifluoroacetic acid", "derivatives" on the 7<sup>th</sup> and the 9<sup>th</sup> line to "derivative", "scheme I" on the 7<sup>th</sup> and the 9<sup>th</sup> line to "scheme", "6-Methylepyridine" on the 9<sup>th</sup> line to "6-Methylpyridine", "formula 2" on the 11<sup>th</sup> and the 13<sup>th</sup> line to "formula II", "formula 3" on the 12<sup>th</sup> and the 14<sup>th</sup> line to "formula III" and "4-morforino" on the 11<sup>th</sup> and the 14<sup>th</sup> line to "4-morpholino" are corrected respectively.
2. "weak ~6 days" paragraph is changed to "the reactions are performed in organic solvents such as methanol, ethanol, isopropanol, dichloromethane, chloroform, acetonitrile; N, N-dimethylformamide, acetone and the like, and in the presence of the weak tertiary organic bases such as pyridine, 2,6-lutidine, 4-dimethylaminopyridine, N,N-dimethylaniline and the like, for a relatively long period of time, namely one day to 6 days at a temperature in the range of 40-80°C" on the 16<sup>th</sup> to the 21<sup>st</sup> lines.

... Cont'd next page

(ix) page 9:

1. "formula 1" on the 3<sup>rd</sup>, 5<sup>th</sup>, 12<sup>th</sup> and 21<sup>st</sup> line to "formula I" and "derivatives" on the 3<sup>rd</sup> line to "derivative" are corrected respectively.
2. "an" is inserted right ahead of "active ingredient" on the 4<sup>th</sup> line.
3. "more than one compound" is changed to "the compound" on the 11<sup>th</sup> line.
4. "or detergent (or surfactant)" is changed to "or surfactant" on the 9<sup>th</sup> line.

(x) page 10:

1. "Example" on the 4<sup>th</sup> line to "Example 1", "4-morforino" on the 4<sup>th</sup> and the 6<sup>th</sup> line to "4-morpholino" and "mL" on the 7<sup>th</sup>, 10<sup>th</sup> and 13<sup>th</sup> line to "ml" are corrected respectively.
2. ", and heated~" is changed to "The mixture was heated to 60°C and stirred for five days at 60°C." on the 7<sup>th</sup> to the 8<sup>th</sup> lines.
3. "solid extracted from the reaction" is changed to "precipitated solid" on the 9<sup>th</sup> line.
4. "stirred for 1 hour" phrase is changed to "the residue was crystallized with 60 ml of methanol, and stirred for 1 hour" on the 12<sup>th</sup> line.
5. "any" and "therein" are deleted on the 10<sup>th</sup> to the 11<sup>th</sup> lines.
6. "with 60 mL of methanol" phrase is deleted on the 11<sup>th</sup> to the 12<sup>th</sup> lines.
7. "Then, the organic layer" to "The product" and "filtered and" to "filtered," are changed respectively on the 12<sup>th</sup> to the 13<sup>th</sup> lines.
8. "to give a solid product. The product was" on the 13<sup>th</sup> to the 14<sup>th</sup> lines is changed to "and".
9. "(89%)" is corrected to "(80%)" on the 15<sup>th</sup> line.

(xi) page 11:

1. "with" is corrected to "into" on the 4<sup>th</sup> line.
2. "with" is inserted right ahead of "the binding" on the 14<sup>th</sup> line.
3. "i.e." is deleted on the 26<sup>th</sup> line.

(xii) page 13:

1. "mL" of Table 1 and on the 13<sup>th</sup> line is corrected to "ml".
2. "above" is inserted right ahead of "table" on the second line.
3. "compounds" on the 2<sup>nd</sup> and the 14<sup>th</sup> line to "compound" and "derivatives" on the 10<sup>th</sup> and the 17<sup>th</sup> line to "derivative" are corrected respectively.
4. "MTT analysis" on the 12<sup>th</sup> line to "MTT assay using HepG 2 cell line", "every" on the 12<sup>th</sup> line to "the" and "they are" on the 14<sup>th</sup> line to "it is" are changed respectively.

... Cont'd next page

5. "according to the present invention" phrase is inserted right ahead of "represented" on the 17<sup>th</sup> line.

(xiii) page 16:

1. "More particularly, ~ to" phrase is changed into ", and more particularly novel~" on the 4<sup>th</sup> to the 5<sup>th</sup> line.
2. "(I)" of formula is corrected to "... (I)".
3. "derivatives" to "derivative" on the 5<sup>th</sup> to the 11<sup>th</sup> lines and "have" to "has" on the 11<sup>th</sup> line are corrected respectively.
4. "(HCV)" is added right after "virus" on the 12<sup>th</sup> line.

As mentioned in the above, the description appearing in the international application based on the replacement sheets submitted herewith is amended to correct errors in specification to the extent that it does not change the scope of the subject matter.

Furthermore, in respect of the title of the invention appearing in the international application based on the replacement sheets submitted herewith, in accordance with PCT section 205, the title of the invention "6-METHYLPYRIDINE DERIVATIVES, METHOD FOR PREPARING THEREOF AND ANTIVIRAL PHARMACEUTICAL COMPOSITION COMPRISING THE SAME" is changed to "6-METHYLPYRIDINE DERIVATIVE, METHOD FOR PREPARING THEREOF AND ANTIVIRAL PHARMACEUTICAL COMPOSITION COMPRISING THE SAME".

your sincerely,

LEE, Duck-Rog